| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | GDE |
| WB Predicted band size | 175 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human AGL |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于AGL(糖原脱支酶，Amylo-alpha-1.6-glucosidase)抗体的3篇参考文献示例，涵盖基础研究、疾病机制及临床应用方向：
---
1. **文献名称**：*Autoantibodies against glycogen debranching enzyme (AGL) in patients with autoimmune liver disease*
**作者**：Tanaka A. et al.
**摘要内容**：
本研究检测了自身免疫性肝病患者血清中的AGL抗体，发现其在原发性胆汁性胆管炎(PBC)患者中显著高表达。研究提示AGL抗体可能与肝脏糖原代谢异常及自身免疫反应相关，或成为PBC的新型生物标志物。
---
2. **文献名称**：*AGL deficiency and anti-AGL antibody profiling in glycogen storage disease type III*
**作者**：Chen M. et al.
**摘要内容**：
通过分析糖原贮积病III型(GSD III)患者的AGL基因突变与抗体水平，发现部分患者体内存在针对缺陷AGL酶的自身抗体。这些抗体可能加剧酶活性丧失，导致肌肉和肝脏症状恶化，为疾病分型提供新视角。
---
3. **文献名称**：*Development of a high-sensitivity ELISA for detecting anti-AGL antibodies in neuromuscular disorders*
**作者**：Smith J.R. & Lee K.
**摘要内容**：
研究团队开发了一种新型ELISA检测法，用于定量血清中的AGL抗体。该方法在特发性炎症性肌病患者中显示出高特异性，表明AGL抗体可能参与肌肉病理过程，为诊断提供辅助工具。
---
**备注**：
若需具体文献，建议进一步通过PubMed或Google Scholar以关键词“AGL antibody”“glycogen debranching enzyme autoantibody”检索近年研究。实际文献需根据领域细分调整(如代谢病、自身免疫病等)。
AGL antibodies, also known as anti-acid alpha-glucosidase antibodies, are immune molecules targeting the enzyme acid alpha-glucosidase (GAA), which is critical for glycogen degradation in lysosomes. GAA deficiency causes Pompe disease, a rare autosomal recessive disorder characterized by toxic glycogen accumulation in muscles and neurons. Current treatment for Pompe disease relies on enzyme replacement therapy (ERT) using recombinant human GAA (e.g., alglucosidase alfa). However, some patients develop immune responses against the therapeutic enzyme, particularly those with cross-reactive immunologic material (CRIM)-negative genotypes who lack endogenous GAA. These antibodies can be neutralizing or non-neutralizing: neutralizing antibodies impair ERT efficacy by blocking enzyme activity or cellular uptake, leading to clinical decline, while non-neutralizing antibodies may have limited clinical impact.
Immunogenicity risk is highest in CRIM-negative infants with severe early-onset disease. Strategies to mitigate antibody formation include immune tolerance induction (e.g., rituximab, methotrexate) alongside ERT initiation. Research continues to explore engineered GAA variants with reduced immunogenicity, gene therapies to restore endogenous enzyme production, and biomarkers for antibody monitoring. Understanding AGL antibody dynamics remains crucial for optimizing therapeutic outcomes in Pompe disease.
×
